<DOC>
	<DOCNO>NCT00936520</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics SAR 1118 within anterior posterior chamber eye plasma subject undergo elective vitrectomy treat escalate concentration study drug approximately 1 week .</brief_summary>
	<brief_title>SAR 1118 Human Subjects Undergoing Pars Plana Vitrectomy</brief_title>
	<detailed_description>SAR 1118 potent selective small molecule lymphocyte function antigen-1 ( LFA-1 ) antagonist may therapeutically useful novel topical anti-inflammatory agent wide variety ocular inflammatory condition include diabetic retinopathy diabetic macular edema . Recent evidence demonstrate topically deliver SAR 1118 ophthalmic solution detect aqueous , vitreous , retina 4 12 hour dose potentially therapeutic level animal model . However , ability current sterile ophthalmic formulation SAR 1118 penetrate sufficiently high therapeutic concentration anterior posterior chamber human unknown .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<criteria>Human subject meet follow criterion enrol : Age ≥18 year BCVA ≤20/40 study eye ( BCVA measure 4M ETDRS ) Male female Current nonsmoker ( last date smoking least 60 day study enrollment ) Surgically eligible undergo elective PPV include , limited , epiretinal membrane , vitreomacular traction , macular hole , retinal detachment . The elective surgery must able schedule least 21 day advance allow time screen initiation study drug . Females must nonpregnant , nonlactating , surgically sterile least 3 month , postmenopausal least 1 year FSH great equal 40 mIU/mL , willing use approve method contraception 35 day prior first study drug administration . Approved method contraception include : nonhormonal IUD spermicide , female condom spermicide , diaphragm spermicide , cervical cap spermicide , use condom spermicide sexual partner sterile sexual partner . Willing able provide write informed consent nature study explain , prior researchrelated procedure . Willing able comply study procedure include followup instruction Individuals eligible participate study include meet following criterion : Vitreous hemorrhage Active retinal detachment Autoimmune disease anterior segment posterior chamber include chronic keratoconjunctivitis sicca , uveitis , iritis/scleritis , blepharitis either eye Glaucoma require topical medication , infectious conjunctivitis , keratitis , endophthalmitis either eye Prior vitrectomy intraocular lens placement , within 90 day Day 0 Previous intravitreal drug delivery administer study eye within following time period Day 0 : Intravitreal steroid give ≤3 month Intravitreal vascular endothelial growth factor inhibitor give ≤2 month Previous participation study investigational drug within 1 month precede Day 0 Any concurrent ophthalmic overthecounter topical ocular pharmaceutical within 30 day Day 0 exception saline tear lubricant . History malignancy , renal insufficiency , hepatic insufficiency Positive serum pregnancy test Use oral , implantable , injectable contraceptive within 30 day 5 halflives contraceptive ( whichever longer ) prior first study drug administration ; patient must refrain types contraceptive treatment period may resume use contraceptive follow 1week observation period . Any history excessive alcohol ( judged Investigator ) illicit drug use/abuse Consumption alcohol illicit drug within one week first study drug administration Use tobacco nicotinecontaining product within 2 month prior first study drug administration Any laboratory abnormality consider clinically significant Investigators Subjects hemoglobin &lt; 12.0 g/dL Any clinically significant acute chronic medical condition would preclude participation clinical study Any history autoimmune disease , immunodeficiency disorder , positive HIV , acute hepatitis A ( IgM positive ) , hepatitis B , C , organ bone marrow transplant Participation ongoing investigational drug medical device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>DME</keyword>
	<keyword>Pars Plana Vitrectomy</keyword>
	<keyword>Ocular Inflammation</keyword>
</DOC>